{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-056421","form_type":"8-K","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2025-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.598342+00:00","generated_at":"2026-05-20T00:23:46.440220+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Liminatus Pharma receives and resolves Nasdaq non-compliance for late 10-Q filing","bullets":["Received Nasdaq notice on May 29, 2025, for non-compliance with Listing Rule 5250(c)(1) due to delayed Form 10-Q.","Filed the overdue Form 10-Q for Q1 2025 on June 2, 2025.","Nasdaq confirmed on June 3, 2025, that the company regained compliance; matter is closed.","Pre-clinical biotech (LIMN) focuses on immune-modulating cancer therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-056421","json":"https://secwatch.observer/filing/0001104659-25-056421.json","markdown":"https://secwatch.observer/filing/0001104659-25-056421.md","text":"https://secwatch.observer/filing/0001104659-25-056421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925056421/0001104659-25-056421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925056421/tm2517129d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T00:23:46.440220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f06ed450d64eb2544ec28c4755520610b054b4f","claim":"Liminatus Pharma, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"May 29, 2025, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Form 10-Q”). On June 2, 2025, the Company filed the Form 10-Q with the U.S. Securities and Exchange Commission. On June 3, 2025, the Company received a letter from the Staff stating that the Company had regained compli","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925056421/0001104659-25-056421-index.htm","confidence":0.99,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"late filing"},{"label":"Rules","value":"5250(c)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}